Thrombolytic Therapy Side Effects: Risks and What to Expect
Thrombolytic (fibrinolytic) therapy (alteplase, tenecteplase, reteplase, streptokinase) dissolves clots in MI, ischemic stroke, PE, DVT. Benefit is time-critical; bleeding is the major risk.
Major Adverse Effects
| Complication | Incidence | Key Details |
|---|---|---|
| Symptomatic intracranial hemorrhage (sICH) | 1–3% (stroke); <1% (MI) | Most feared; mortality ~50%. Risk factors: age >80, severe stroke (NIHSS>10), HTN, anticoagulants, early CT changes. |
| Major extracranial bleeding | 2–5% | GI, GU, retroperitoneal, access site. Transfusion-requiring. |
| Minor bleeding | 10–30% | Epistaxis, gum, ecchymosis, hematuria. |
| Hypotension | Common | Vasodilation from bradykinin; usually transient. Monitor closely. |
| Allergic reactions | 1–2% (streptokinase higher) | Rash to anaphylaxis. Premedicate for streptokinase. |
| Reperfusion arrhythmias | Common in MI | Accelerated idioventricular rhythm, VF/VT—usually self-limited. |
| Reperfusion injury / no-reflow | Variable | Oxidative stress, inflammation, microvascular obstruction. |
| Rebound thrombosis | Rare | Paradoxical re-occlusion if underlying thrombogenic state unaddressed. |
